News Release

Effectiveness, safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease

JAMA Cardiology

Peer-Reviewed Publication

JAMA Network

About The Study: In this post hoc secondary analysis of 10,678 participants with atherosclerotic cardiovascular disease from a randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of heart attack, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.

Authors: Mark B. Effron, M.D., of the University of Queensland-Ochsner Clinical School in New Orleans, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.